Resveratrol effects on cancer cells

Authors

DOI:

https://doi.org/10.33448/rsd-v11i6.28841

Keywords:

Antioxidants; Cancer; Resveratrol.

Abstract

Introduction: Resveratrol has been systematically investigated for its anticancer, anti-inflammatory, cardioprotective, neuroprotective and antidiabetic effects indicated by several. Objective: To understand the antineoplastic action of RESV in reducing the development of cancer cells Methodology: This is a literature review with a descriptive approach. Results: From the study of the literature, it was possible to observe the first step towards the extraordinary results that will contribute to open a range of systematic research. Today we have in our favor the technology that benefits us from these exquisite substances from the skin and seed of the grape, incorporating more natural treatments and less damage to the body. Discussion of results: Resveratrol helps fight cancer associated with chemotherapy. Researcher at UFRJ that the use of this substance reduces the amount of the drug to be administered in chemotherapy and minimizes the effects of the explanatory research of the effects. Conclusion: Through the studies carried out, it was possible with RESV that it is a strong ally to play a leading role in terms of providing a new path of knowledge and diligence in favor of cancer therapy.

References

Abbas, A. K., et al. (1994). Cellular and molecular immunology. 2nd. Philadelphia: W. B. Saunders Co., 356-375.

Aires, V., Limagne, E., Cotte, A.K., Latruffe, N., Ghiringhelli, F., & Delmas, D. (2013). Resveratrol metabolites inhibit human metastatic colon cancer cells progres- sion and synergize with chemotherapeutic drugs to induce cell death. Mol. Nutr. Food Res. 57, 1170–1181.

Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., & Takada Y. (2004). Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Research, 24(5), 2783-840.

Alves, L. C. A. (2015). O resveratrol como molécula antienvelhecimento. 69f. Dissertação Mestrado em Ciências Farmacêuticas pela Faculdade de Ciências e Tecnologias da Saúde de Lisboa, Lisboa.

Anton, S. D., Embry, C., Marsiske, M., Lu, X., Doss, H., Leeuwenburgh, C., et al. (2014). Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp Gerontol, 57, 181-7. 48.

Antunes, L. M. G., & Araújo, M. C. P. (2000). Mutagenicidade e antimutagenicidade dos principais corantes para alimentos. Revista de Nutrição, 13(2), 81-8.

Apostolidou, C., Adamopoulos, K., Iliadis, S., & Kourtidou-Papadeli, C. (2015). Alterations of antioxidant status in asymptomatic hypercholesterolemic individuals after resveratrol intake. Int J Food Sci Nutr, 67(5), 541-52. 45.

Barbosa, G. L. R., Pimenta, L. A., & Almeida, S. M. (2016). Micro-CT evaluation of the radioprotective effect of resveratrol on the mandibular incisors of irradiated rats. Braz Oral Res, 30(1).

Barbosa, K. B. F., et al. (2010). Estresse oxidativo: conceito, implicações e fatores modulatórios. Revista de Nutrição, 23(4), 629-643.

Barreiros, S. B. L. A., David, M. J., & David, P. J. (2006). Extresse oxidativo: relação entre geração de espécies reativas e defesa do organismo. Quimica Nova, 29(1), 113-223.

Bo, S., Ciccone, G., Castiglione, A., Gambino, R., De Michieli, F., Villois, P., et al. (2013). Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem, 20(10), 1323-1331. 44.

Brasil. (2016). Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estimativa de incidência de câncer no Brasil. http://www.inca.gov.br/estimativa/2016/.

Chapman, M. J. (2006). Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease, Pharmacol Ther. 111(3), 893-908. 49.

Chekalina, N. I., Kazakov, Y. M., Mamontova, T. V., Vesnina, L. E., Kaidashev, I. P. (2016). Resveratrol more effectively than quercetin reduces endothelium degeneration and level of necrosis factor in patients with coronary artery disease. Wiad Lek, 69(3 pt 2), 479-83.

Cottart, C. H., Nivet-Antoine, V., Laguillier-Morizot, C., & Beaudeux, J. L. (2010). Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 54, 7–16.

Cross, A. J., Boca, S., Freedman, N.D., Caporaso, N. E., Huang, W. Y., Sinha, R., Sampson J, N., Moore, S. C. (2014). Metabolites of tobacco smoking and colorectal cancer risk. Carcinogenesis, 35:1516–1522.

Cullen, J. P., Morrow, D., Jin, Y., et al. (2007). O resveratrol inibe a expressão e a atividade de ligação do receptor quimiotático de proteína monócito-1, CCR2, em monócitos THP-1. Aterosclerose.

Dash, S., Xiao, C., Morgantini, C., Szeto, L., Lewis, G. F. (2013). High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler Thromb Vasc Biol. 33(12), 2895-901. 47.

Delmas, D., Rébé, C., Lacour, S., et al. (2003). Resveratrol-induced Apoptosis Is Associated with Fas Redistribution in the Rafts and the Formation of a Death-inducing Signaling Complex in Colon Cancer Cells. The Journal Of Biological Chemistry. 278(42), ,41482–41490.

Devita, Jr., Vincent, T., Hellman, Samuel, & Rosenberg, S. A. (2005). Cancer: principles and practice of oncology. 7. ed. Philadelphia: Lippincott Williams & Wilkins, 3120.

Dornas, W.C., Oliveira, T.T.D., Rodrigues-Das-Dores, R.G., Santos, A.F.D., & Nagem, T.J. (2009). Flavonoides: potencial terapêutico no estresse oxidativo. Revista de Ciências Farmacêuticas Básica e Aplicada, 28(3), 41-249.

Frampton, G., Lazcano, E., Huang L., Mohamad, A., & Demorrow S. (2010). Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. Lab Invest. Sep; 90(9), 1325–1338.

Fujitak, K., Otani, H., Jo, F., Jo, H., Nomura, E., Iwasaki, M., et al. (2011). Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res. 31(11), 842-7. 33.

Gong, W. H., Zhao, N, Z. M., Zhang, Y. X., Zhang, L., & Yan, J. B. (2017). The inhibitory effect of resveratrol on COX-2expression in human colorectal cancer:a promising therapeutic strategy. European Review for Medical and Pharmacological Sciences, 21, 1136-1143.

Guyton, A.C., & Hall, J.E. (2011). Tratado de Fisiologia Médica. 12.ed. Rio de Janeiro: Elsevier, 1216.

Harper, C. E., Patel, B. B. J., Wang, et al. (2007). O resveratrol suprime a progressão do câncer de próstata em camundongos transgênicos. Carcinogênese.

Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., Hegarty, B., et al. (2011). Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases – safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila), 4(9):1419-25. 31.

Hsieh, T.C., & Wu, J. M. (2010). Resveratrol: Biological and pharmaceutical properties as anticancer molecule. Biofactors, 36(5), 360-9.

Joseph, A., David, A. (2006). Sinclair. Therapeutic potential of resveratrol: the in vivo evidence. Nature reviews | drug discovery. 493-506.

Kay, C. D. (2010). The future of flavonoid research. Br J Nutr. 104(S3), S91-S95. 52.

Kitada, M., Kume, S., Imaizumi, N., & Koya, D. (2011). Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/ SIRT1-independent pathway. Diabetes, 60, 634-43. DOI: http://dx.doi.org/10.2337/db10-0386.

Kroon, P.A., Iyer, A., Chunduri, P., Chan, V., & Brown, L. (2010). The cardiovascular nu-trapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Curr. Med. Chem. 17, 2442–2455.

Lagouge, M., Argmann, C., Gerhart-Hines, Z., et al. (2006). O resveratrol melhora a função mitocondrial e protege contra doenças metabólicas ativando SIRT1 e PGC-1alfa. Célula.

Leal, B. J., Carvalho, O. F., Gonçaves, C. D., Leal, B. J., Silva, L. C. D., Junior, C. C. L., & Hoefel, L. A. (2017). Resveratrol: Composição Química e seus Benefícios a Saúde. Revista Brasileira de Obesidade Nutrição e Emagrecimento, São Paulo, 11(67), 620-629.

Li, W., Ma, J., Ma, Q., Li, B., Han, L., Liu, J., Xu, Q., Duan, W., Yu, S., Wang, F., & Wu, E. (2013). Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-kappaB pathway. Curr. Med. Chem. 20, 4185–4194.

Lin, H.Y., Shih, A., Davis, F.B., Tang, H.Y., Martino, L.J., Bennett, J.A., & Davis, P.J. (2002). Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J. Urol. 168, 748–755.

Liu, B. L, Zhang, X, Zhang, W., & Zhen, H. N. (2007). New enlightenment of French paradox: resveratrol’s potential for cancer chemoprevention and anti-cancer therapy. Cancer Biol Ther. 6 (12), 1833-36.

Magyar, K., Halmosi, R., Palfi, A., Feher, G., Czopf, L., Fulop, A., et al. (2012). Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 50(3), 179-87.

Matos, S. R., Baroncini, V. A. L., Précoma, B. L., Winter, G., Caron, L. H. P., Kaiber, F., & Précoma, B.D. (2012). Resveratrol provoca efeitos antiaterogênicos em modelo animal de aterosclerose. Sociedade Brasileira de Cardiologia, Curitiba, 98(2), 136142.

Ndiaye, M., Kumar, R., & Ahmad, N. (2011). Resveratrol in cancer management: where are we and where we go from here. Ann. NY Acad. Sci. 1215, 144–149.

Langcake, P., & Pryce, R. J. (1977). The production of resveratrol and the viniferins by grapevines in response to ultraviolet radiation. Phytochemistry. 16(8), 1193-96.

Perovano, D. G. (2014). Manual de Metodologia Científica. Paraná: Editora Juruá

Poulsen M, M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stodkilde-Jorgensen, H., et al. (2013). High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 62(4), 1186-95. 32.

Queimaduras, J., Yokota, T., Ashihara, H., Lean M. E., Crozier, A. (2002). Alimentos vegetais e fontes herbáceas de resveratrol. J Agric Food Chem.

Saiko, P., Szakmary, A., Jaeger, W., & Szekeres, T. (2008). Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad. Mutat. Res. 658, 68–94.

Sautter, C. K., Denardin, S., Alves, A. O., Mallmann, C. A., Penna, N. G., & Hecktheuer, L. H. (2005). Determinação de resveratrol em sucos de uva no Brasil. Ciênc. Tecnol. Aliment., Campinas, 25(3), 437-442.

Savio, M., Ferraro, D., Maccario, C., Vaccarone, R., Jensen, L.D., Corana, F., Mannucci, B., Bianchi, L., Cao, Y., & Stivala, L.A. (2016). Resveratrol analogue 4,4 - dihydroxy-trans-stilbene potently inhibits cancer invasion and metastasis. Sci. Rep. 6, 19973.

Semba, R. D., Ferrucci, L., Bartali, B., Urpií-Sarda, M., Zamora-Ros, R., Sun, K, et al. (2014). Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med. 174(7), 1077-84. 51.

Seyyedebrahimi, S., Khodabandehloo, H., Nasli, E. E., & Meshkani, R. (2018). The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Acta Diabetol. 55(4), 341-53, 46.

Sharmila, S., Gyanendra, S., & Rakesh, K. (2007). Srivastava. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Frontiers in Bioscience, 12, 4839-4854.

Shik, A., Zhang, S., Cao, H.J., Boswell, S., Wu, Y.H., Tang, H.Y., Lennartz, M.R., Davis, F.B., P.J., & Lin, H.Y. (2004). Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol. Cancer Ther. 3, 1355–1364.

Soleas, G. J., Diamandis, E.P., & Golberg D.M. (1997). Resveratrol: a molecule whose time has come? And gone?. Clin Biochem, 30(2):91-113.

Tessitore, L., Davit, A., Sarotto, I., et al. (2000). Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis, 21, 1619–22.

Tomé-Carneiro, J., Gonzálvez, M., Larrosa, M., Yánez-Gascón, M., Garcia-Almagro, F. J., Ruiz-Ros, J.A., et al. (2013). Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. Ann N Y Acad Sci. 1290, 37-51.

Valenzano, D. R., Terzibasi, E., Genade, T., et al. (2006). O resveratrol prolonga a vida útil e retarda o início de marcadores relacionados à idade em um vertebrado de curta duração. Curr Biol.

Whitsett, T., Carpenter, M., & Lamartiniere, C. A. (2006). O resveratrol, mas não o EGCG, na dieta suprime o câncer mamário induzido por DMBA em ratos. J Carcinog.

Wong, R.H., Howe, P.R., Buckley, J.D., Coates, A.M., Kunz, I., & Berry, N.M. (2011). Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 21(11), 851-6. 34.

Xia, N., Daiber, A., Forstermann, U., & Li, H. (2017). Antioxidant effects of resveratrol in the cardiovascular system. Br J Pharmacol. 174(12), 1633-46. 50.

Xu, Q., Zong, L., Chen, X., Jiang, Z., Nan, L., Li, J., Duan, W., Lei, J., Zhang, L., & M.A., J. (2015). Resveratrol in the treatment of pancreatic cancer. Ann. NY Acad. Sci. 1348, 10–19.

Published

19/04/2022

How to Cite

SOUZA, G. do N. B. de .; FERREIRA, J. C. de S. Resveratrol effects on cancer cells. Research, Society and Development, [S. l.], v. 11, n. 6, p. e3711628841, 2022. DOI: 10.33448/rsd-v11i6.28841. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/28841. Acesso em: 22 may. 2022.

Issue

Section

Review Article